f-star buys back royalties, TVM Capital invests
March 28, 2008

f-star opens research site in Cambridge, UK
March 12, 2008

f-star establishes Scientific Advisory Board
December 12, 2007

f-star increases Series A to EUR 9.0m
November 28, 2007

f-star appoints Geert Mudde as CSO
September 25, 2007

f-star raises EUR 6.0m in Series A financing
September 10, 2007

EUR 1.5m seed financing from Atlas Venture
January 8, 2007

f-star is a next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.

Modular Antibody Technology allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, small sized antibody fragments with full antibody functionality (Fcab™) or full length antibodies with additional functionality (mAb²) can be created.

Founded in 2006, the Company currently employs more than twenty highly qualified people in Vienna, Austria and a team of highly experienced scientists at its second research site in Cambridge, UK. In its Advisory Board, the Company is supported by pioneers in the research and development of monoclonal antibodies including Sir Ravinder Maini, Prof. Anthony Rees and Sir Gregory Winter.

f-star’s management team has many years of experience in the biotech and pharmaceutical industry, covering antibody engineering, pharmaceutical development, intellectual property, business development and finance.

f-star enjoys the strong financial support from a world-class group of life science investors including Aescap Venture, Atlas Venture, Novo A/S and TVM Capital.

BioPartnering Europe
London, UK
October 12-14, 2008

Bio Japan
Yokohama, JP
October 15-17, 2008